Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418.
Alfonso Cabello-ÚbedaAlicia González BaezaJesús Troya GarcíaSara de La Fuente MoralMaría Novella MenaAdriana Pinto MartínezRafael MicánMiguel GórgolasGuillermo Cuevas TascónAlberto Díaz de SantiagoJosé Sanz MorernoDavid Rial CresteloCarmen Busca ArenzanaJosé Ignacio Bernardino SernaMariana Díaz AlmirónJoanna CanoHerminia EstebanIgnacio Pérez-ValeroPublished in: Open forum infectious diseases (2022)
In patients reporting subclinical sleep disturbances without insomnia, switching from dolutegravir/lamivudine/abacavir to darunavir/cobicistat/emtricitabine/tenofovir alafenamide was associated with better sleep quality and improvements in mood and NS.
Keyphrases
- sleep quality
- hiv infected patients
- antiretroviral therapy
- human immunodeficiency virus
- hiv infected
- hiv positive
- depressive symptoms
- hiv aids
- physical activity
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- emergency department
- patient reported outcomes
- adverse drug
- bipolar disorder